Prostate Cancer - Results from #800

REVIEW UroToday

Progression of bone metastases in patients with prostate cancer - Automated detection of new lesions and calculation of bone scan index, "Beyond the Abstract," by Prof. Anders Bjartell, MD, PhD and Prof. Lars Edenbrandt, MD, PhD, et al March 6, 2014

Volumetric-modulated arc therapy for a pelvic lymph node metastasis from prostate cancer, "Beyond the Abstract," by Finn Edler von Eyben, et al February 28, 2014

Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells, "Beyond the Abstract," by Priyamvada Rai, PhD February 27, 2014

Regulation of the tumor suppressor PTEN through exosomes: A diagnostic potential for prostate cancer, "Beyond the Abstract," by Khalid Al-Nedawi, PhD February 26, 2014

Assessment of interfractional prostate motion in patients immobilized in the prone position using a thermoplastic shell, "Beyond the Abstract," by Itaru Ikeda, PhD student February 21, 2014

Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer, "Beyond the Abstract," by Katri Selander, MD, PhD and Markku Vaarala, MD, PhD February 17, 2014

A walnut-enriched diet reduces the growth of LNCaP human prostate cancer xenografts in nude mice, "Beyond the Abstract," by Russel J. Reiter, PhD, Dr.h.c.mult February 13, 2014

Prospective evaluation of urinary incontinence, voiding symptoms and quality of life after open and robot-assisted radical prostatectomy, "Beyond the Abstract," by Inge Geraerts, PhD, et al February 12, 2014

Label-free analysis of prostate acini-like 3D structures by lensfree imaging, "Beyond the Abstract," by Nathalie Picollet-D’hahan, PhD, et al. February 7, 2014

NADiA® ProsVue™ PSA slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy, "Beyond the Abstract," by Judd W. Moul, MD January 30, 2014

Health care costs for state transition models in prostate cancer, "Beyond the Abstract," by Karen E. Bremner, BSc January 28, 2014

%p2PSA and PHI may prove more accurate than tPSA, fPSA, and %fPSA in predicting prostate cancer in men with a positive family history, "Beyond the Abstract," by Alberto Abrate, MD, et al January 28, 2014

11βOH-androstenedione – jumping into the androgen pool – a role in CRPC, "Beyond the Abstract," by Amanda C. Swart, PhD January 24, 2014

Defining the optimal approach to the patient with postradiation PSA recurrence using outcome data from a prospective randomized trial, "Beyond the Abstract," by Miranda B. Kim, MD, MBA January 21, 2014

Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer, "Beyond the Abstract," by Naseruddin Höti, MPhil, PhD, DSc and Ronald Rodriguez, MD, PhD January 17, 2014

Testosterone boosts for treatment of castration resistant prostate cancer, "Beyond the Abstract," by Paul Thelen, PhD January 17, 2014

Use of hyaluronic acid-carboxymethylcellulose adhesion barrier on the neurovascular bundle and prostatic bed to facilitate earlier recovery of erectile function after robotic prostatectomy, "Beyond the Abstract," by Jae Young Joung, MD, PhD January 15, 2014

Patient time and out-of-pocket costs for long-term prostate cancer survivors in geographically diverse populations of a large Canadian province, "Beyond the Abstract," by Claire de Oliveira, MA, PhD, et al January 10, 2014

Determinants of the combined use of external beam radiotherapy and brachytherapy for low-risk, clinically localized prostate cancer, "Beyond the Abstract," by Ruben G. W. Quek, PhD and Viraj A. Master, MD, PhD, FACS January 9, 2014

β4 Integrin signaling induces expansion of prostate tumor progenitors, "Beyond the Abstract," by Toshiaki Yoshioka, Javier Otero, and Filippo G. Giancotti December 20, 2013

Page 41 of 57